Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

Abstract: The invention relates to a kit to be used for the identification of a secretion cassette, which in eukaryotic cells gives rise to a higher level of synthesis/secretion of a protein of interest, the coding sequence of which being flanked by the first and the second set of genetic elements, respectively, compared to the other secretion cassettes present in the kit containing the coding sequence at the corresponding position, as well as to a method wherein the kit is used and the use of the kit, whereby the best secretion cassette will be obtained.

Abstract: The present invention relates to a method for diagnosing aggressiveness and/or genetic instability of a cancer in a patient from a cancer sample of the patient. The method includes measuring in vitro the expression level of the POLQ gene and the expression level of a control gene in the patient cancer sample, calculating an expression level ratio of the expression level of POLQ to the expression of the control gene in the patient cancer sample, comparing the expression level ratio to a corresponding threshold value, and diagnosing cancer aggressiveness and genetic instability if the POLQ expression level ratio is superior to a corresponding threshold value. Dedicated microarrays and kits are also described, as well as a method of selecting a suitable treatment.

Abstract: The invention relates to a method for the in vitro detection and/or differentiation and/or progress observation of pathophysiological conditions with the aid of sample nucleic acids, including determination of gene activities by means of a plurality of polynucleotides, determination of gene activities of at least one internal reference gene, and formation of an index value from the single determined normalized gene activities of a multigene biomarker indicating the pathophysiological condition.

Abstract: The present invention provides tangential flow filtration devices and methods for enriching a heterogenous mixture of blood constituents for leukocytes by removal of non-leukocyte blood constituents. In one particular embodiment the device can provide a composition enriched in monocytes.

Abstract: A method based is provided for determining the toxicity of engineered nanomaterials (NM). The method comprises in vitro assays for oxidative stress associated with exposure to engineered NM, which comprise assays for: reactive oxygen species production; phase II and glutathione antioxidant molecule expression; activation of MAP and NF-kappa B kinase signaling cascades; production of cytokines, chemokines and adhesion molecules; mitochondrial perturbation and apoptosis; and cellular uptake and subcellular localization of the NM. The method further comprises in vivo assays for oxidative stress in subjects exposed to NM.

Abstract: There is provided a method for evolving an orthogonal rRNA molecule, comprising the steps of: providing one or more libraries of mutant orthogonal rRNA molecules and introducing the libraries into cells such that the orthogonal rRNA is incorporated into ribosomes to provide orthogonal ribosomes; providing one or more orthogonal mRNA molecules which (i) are not translated by natural ribosomes, and (ii) comprise one or more orthogonal mRNA codons; assaying the translation of the orthogonal mRNA and selecting the orthogonal rRNA molecules which translate the orthogonal mRNA, wherein the assay in step (c) requires translation of one or more orthogonal mRNA codons in the orthogonal mRNA; and orthogonal ribosomes incorporating such rRNA molecules.

Abstract: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.

Abstract: Provided herein is a method for inducing cell death by inducing heat shock response in a cell in combination with inhibiting adaptive heat shock response. Also provided are methods for preventing cancer, treating intracellular parasite infections, and inflammation-associated conditions.

Abstract: The present invention provides a method for producing a mesenchymal stem cell having an ability to differentiate into a myoblast by culturing a pluripotent stem cell derived from a human or animal, including: i) preparing the pluripotent stem cell that has been cryopreserved, ii) sub-culturing the prepared pluripotent stem cell in an undifferentiated state for a prescribed number of times, iii) culturing the subcultured pluripotent stem cell under conditions that enable induction of differentiation into an adipocyte in vitro, and iv) separating and collecting a CD105-positive cell during the culturing process.

Abstract: Provided are methods and compositions for constructing stable mammalian embryonic epithelial tissues and organs as well as constructing kidney tissue, and treating renal failure. Disclosed are methods of using an active epithelial growth factor having the capability of effectuating induction of growth and morphogenesis is cells.

Abstract: This invention relates to the production of biomaterials with variable stiffness by subjecting a gel which varies in at least one dimension to plastic compaction. These biomaterials may be useful, for example, for the directional control or guidance of cells within tissue equivalent implants.

Abstract: A process for mask-free localized grafting of organic molecules capable of being electrically activated, onto a composite surface comprising conductive and/or semiconductive portions, by placing said organic molecules in contact with said composite surface, in which said grafting is performed electrochemically in a single step on chosen, defined areas of said conductive and/or semiconductive portions, said areas being brought to a potential higher than or equal to a threshold electrical potential determined relative to a reference electrode, said threshold electrical potential being the potential above which grafting of said organic molecules takes place.

Abstract: Cell expansion systems and methods of use are provided. The cell expansion systems generally include a hollow fiber cell growth chamber, and first and second circulation loops (intracapillary loops and extracapillary loops) associated with the interior of the hollow fibers and exterior of the hollow fibers, respectively. Detachable flow circuits and methods of expanding cells are also provided.

Abstract: A unitary apparatus for isolating cells from adipose tissue including a lipid separation processor with a dispersing head equipped with a plurality of ports and a digestion chamber for dissociation of the constituent cells disposed in adipose tissue. The lipid separating apparatus is useful for the separation of lipids and adipocytes from a mixed cell population. A cell seeding chamber may be attached to the cell isolation apparatus. The components of the apparatus may be packaged in modular kit form.

Abstract: The present invention provides a peptide having 2 to 10 amino acids or a derivative thereof which is able to restore wild type function of human p53, for use in therapy; and a method of screening a library of molecules for the ability of members of that library to restore or modify the function of a target protein in an intra-cellular environment, which method comprises introducing the library into host cells which have a reporter system which allows the identification of those cells in which the function of the target protein has been restored or modified.

Abstract: A method of estimating blood pressure Pulse Wave Velocity (PWV) in the aorta from a recording of a pressure waveform at a single site. The method comprises the following steps: 1. measuring the patient's arterial pressure relative to time in order to estimate a central pressure waveform (CPW); 2. estimating the patient's aortic pressure pulse transit time (PPTT) from the CPW; 3. estimating the patient's carotid to femoral arterial distance from the patient's physical characteristics; and 4. dividing the patient's estimated carotid to femoral arterial distance by the patient's estimated PPTT to estimate the patient's PWV.

Abstract: The invention provides a non-naturally occurring microbial organism having 4-hydroxybutanoic acid (4-HB) and 1,4-butanediol (1,4-BDO) biosynthetic pathways. The pathways include exogenous nucleic acids encoding a) an ?-ketoglutarate decarboxylase; b) a 4-hydroxybutanoate dehydrogenase; c) a 4-hydroxybutyryl-CoA:acetyl-CoA transferase or a butyrate kinase and a phosphotransbutyrylase; d) an aldehyde dehydrogenase, and e) an alcohol dehydrogenase, wherein the exogenous nucleic acids are expressed in sufficient amounts to produce 1,4-butanediol (1,4-BDO). Also provide is a method for the production of 1,4-BDO. The method includes culturing the non-naturally occurring microbial organism having 4-HB and 1,4-BDO biosynthetic pathways substantially anaerobic conditions for a sufficient period of time to produce 1,4-BDO.

Abstract: The invention features methods of analyzing the kinetics properties of transfection reactions. Also featured are methods for creating structural promoters which are effectively unregulated by enhancers and repressors. The structural promoters are significantly more active than the native promoter sequences upon which they are based.

Abstract: An adoptive immunotherapy using ex vivo-generated regulatory T cells may be used for the suppression of undesireable immune response. T cells are to be obtained from the patient's blood, and upon exposure to a set of toxins from the pathogen A. actinomycetemcomitans, the population of regulatory T cells will be enriched ex vivo and adoptively transferred back to the patient. The novel aspect of the present invention is that it generates large numbers of type 1 regulatory T cells, which secrete Interleukin-10.